

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 0233)

GENETEL'S HPV PRODUCT SCORES 100% IN THE SECOND WHO HPV LABNET PROFICIENCY STUDY

The board of directors of Mingyuan Medicare Development Company Limited (the “Company”) is pleased to announce that the Global HPV Laboratory Network of the World Health Organization (“WHO”) recently announced the results of the second HPV DNA Proficiency Study (the “Study”). Sixty-one laboratories from six WHO regions participated in the Study, in which the sensitivity and specificity of HPV DNA detection and typing products routinely used in the laboratories worldwide were evaluated. The results show that only three HPV DNA products, including one developed by Genetel Pharmaceuticals (Shenzhen) Co., Ltd (“Genetel”), a wholly owned subsidiary of the Company, achieved the score of 100% proficiency.

HPV, the short form of human papillomavirus, is the major cause for cervical cancer. More than 80% of women will have an HPV infection in their lifetime. It has been identified that 13 high-risk HPV viruses, if left undetected and untreated, would lead to the development of cervical cancer. Cervical cancer is the second biggest cause of female cancer mortality worldwide.

Genetel, a limited liability company incorporated in the PRC on 3 November 2004 for the research and development of DNA technology and products. SNIPER™ technology is a patented technology developed and owned by Genetel. Genetel's SNIPER™ HPV Fluorescence Detection kit can simultaneously detect 13 high-risk HPV viruses, offering the most sensitive and affordable product for early screening of cervical cancer in large populations.

By order of the Board
Mingyuan Medicare Development Company Limited
銘源醫療發展有限公司*
Kenny Poon
Company Secretary

Hong Kong, 23 September 2009

As at the date of this announcement, the executive directors are Mr. Yao Yuan (Executive Chairman), Mr. Chien Hoe Yong, Henry (CEO), Mr. Iu Chung, Mr. Hu Jun, and Mr. Yu Ti Jun; non-executive directors are Mr. Yang Zhen Hua and Mr. Ma Yong Wei; the independent non-executive directors are Dr. Lam Lee G., Mr. Hu Jin Hua and Mr. Lee Sze Ho, Henry.

* *For identification purposes only*